Treatment of multiple keratoacanthomas with erlotinib

David C. Reid, Joan Guitart, Mark Agulnik, Mario E. Lacouture

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


An 82-year-old male presented with numerous pruritic erythematous nodules over his trunk and extremities. Histopathology was consistent with keratoacanthomas. Given the extent of his disease, medical therapy was recommended. Based on phosphorylated epidermal growth factor receptor expression in lesional keratinocytes, treatment with erlotinib 150 mg daily was initiated, with rapid improvement in the number and appearance of nodules. Immunohistochemistry following treatment revealed a decrease in lesional pEGFR expression, consistent with inhibition of this receptor activation. This is the first report of multiple keratoacanthomas responding to therapy with an EGFR tyrosine kinase inhibitor, and it supports an emerging role for the use of EGFR inhibitors in the management of cutaneous malignancies.

Original languageEnglish (US)
Pages (from-to)413-415
Number of pages3
JournalInternational Journal of Clinical Oncology
Issue number4
StatePublished - Aug 2010


  • Cutaneous malignancy
  • Epidermal growth factor receptor
  • Erlotinib
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Surgery


Dive into the research topics of 'Treatment of multiple keratoacanthomas with erlotinib'. Together they form a unique fingerprint.

Cite this